Astellas pays $240M for Vir's cancer drug Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M Tue W Th F 24 February, 2026

Rethink what's possible for mature products — Download the playbook sponsored by Cencora

presented by Health Eco­nom­ic Out­comes of the On­co­type DX Breast Re­cur­rence Test at a Pop­u­la­tion Health Lev­el

SPOTLIGHT In Focus Exclusive: First test of gene therapy for rare form of autism is underway

news Novo Nordisk’s triple-G is competitive with Lilly in obesity, but likely to be second to market Pfizer buys China rights to Sciwind’s approved GLP-1 drug in metabolic push Hims says it spoke with stakeholders to pull weight loss pill New biotech Slate Medicines raises $130M for migraine drug from China Astellas pays $240M cash for Vir's prostate cancer drug Hungary's Turbine raises $25M Series B to build virtual experiments A new ALS drug showed positive signs in early study, but questions remain for pivotal trial

Innovation in biopharmaceuticals: A conversation with Fujifilm leaders sponsored by Fujifilm From structure to selectivity: Federated AI for collaborative binding affinity prediction sponsored by Rhino Federated Computing

After years of rough sledding, biotech investors are getting back to work. Join us for a data-driven look at the field’s top VCs and their strategies for 2026. Get your spot now.

ENDPOINTS PHARMA FDA unveils long-awaited guidance on new pathway for individualized therapies Fortress to sell priority review voucher for $205M China's MGI sells US subsidiary Complete Genomics after Biosecure Act stalled ambitions AbbVie budgets $380M for obesity and neuroscience API facilities in Chicago

in case you missed it 1. Updated: Gilead to buy cell therapy partner Arcellx in deal valued at $7.8B 2. Updated: Novo Nordisk’s CagriSema beaten by Lilly’s Zepbound in head-to-head obesity trial 3. Flagship's Generate targets $2B+ valuation with Nasdaq IPO 4. Gossamer Bio’s potential Winrevair competitor fails pivotal trial 5. China-to-West pace escalates as Frontier, Harbour do licensing deals with GSK, Solstice